There was a problem adding this course to your account. Please try again in a few minutes. If the problem persists, you can contact our support department at (877) 880-1335.
Adding Registration, Please wait...
You must be logged in to perform this action.
Log in
Cancel
Novel and Emerging Pharmacotherapies for Treating Hypertension
Credit(s):
1.25 Contact Hour(s) of CE; 0.5 of which may be applied towards Pharmacology
Program Number:
26047746
Original Program Date:
May 7, 2026
Duration:
1 hour 15 minutes
Access:
Available until May 31, 2027
Date:
May 7, 2026 12:00 PM - 1:15 PM ((GMT-06:00) Central Time (US & Canada))
Released: 04/16/2026 Expires: 05/31/2027 (subject to change)
CE for this activity will not be available after this date.
Webinar Date and Time:5/7/2026 from 12:00-1:15 PM CT
Overview Hypertension remains a leading modifiable cause of cardiovascular morbidity and mortality, yet control rates continue to decline due to persistent practice gaps such as undertreatment, therapeutic inertia, and challenges in managing resistant hypertension. This activity provides nurse practitioners with an updated review of the hypertension landscape, including current guidelines, risk-based treatment strategies, and key distinctions between uncontrolled and resistant hypertension. Learners will also explore contributing factors such as medication adherence, secondary causes, and social determinants of health that impact patient outcomes.
A central focus of this program is the evolving role of novel and emerging antihypertensive therapies. Participants will examine new pharmacologic classes—including aldosterone synthase inhibitors, non-steroidal mineralocorticoid receptor antagonists, endothelin receptor antagonists, and RNA-based therapies—along with the latest clinical trial evidence supporting their use. Emphasizing patient-centered, individualized care, this activity equips nurse practitioners with practical strategies to integrate emerging treatments and optimize management of patients with complex or resistant hypertension.
Objectives
Describe the prevalence and overarching clinical gravity of hypertension (HTN).
Examine established expert consensus and unbridged practice gaps in HTN management.
Differentiate between uncontrolled and resistant HTN, emphasizing the implications for clinical decision-making.
Summarize the pharmacology and clinical trial evidentiary base for novel and emerging antihypertensive therapeutics.
Design individualized treatment plans for patients with resistant HTN, integrating a synthesis of patient-specific, disease-specific, and treatment-specific factors.
Disclosure This program was planned in accordance with AANP CE Standards and Policies.
Speaker Disclosures:
Wendy Wright
Nothing to disclose.
Midge Bowers
Nothing to disclose.
All relevant financial relationships have been mitigated. This CE activity is supported by AANP. All Planners involved in this activity have no relevant financial relationships to disclose.
This educational activity is supported by an independent medical educational grant from AstraZeneca. Disclaimer Individuals who have contributed to the CE Center were carefully selected for their knowledge and experience in the subject area under review. This presentation is informational only and may contain opinions of the authors from their personal experience that do not necessarily express the opinions of the American Association of Nurse Practitioners (AANP). The activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings. Clinical practice is a constantly changing process and new information becomes available every day. Neither AANP nor the contributing individuals can warrant that the material will continue to be accurate, nor do they warrant that the material is completely free of errors upon publication. Attendees and participants should appraise the information presented critically and are encouraged to consult appropriate resources for any product or device mentioned in this program.
CE Credit Instructions
Read this activity description, including objectives and disclosures.
Complete the Pretest associated to the activity. (NOTE: The pre-test must be submitted in order for the webinar to be accessible on the day of the event)
Complete the educational content completely:
Webinar Presentation: Attend the live webinar or watch the recorded on-demand video of the webinar.
To access your Webinar the day of the event, click the green Play button on the My CE Activities page of your account.
Review all additional materials provided (handouts, post-test reviews, any other downloadable resources).
After completing all content, click on the blue Next Stepsbutton:
Complete the post-test.
Submit the evaluation to receive full AANP CE/Rx credit.
Webinar Support Information
Test your device:
Before the event, we recommend testing your system to see if it is compatible for GoToWebinar.
When contacting InReach support by any method above, make sure to let the support representative know that you are an AANP learner and that you are attempting to gain access to an event that is about to start or has already started. This will help expedite your support service.
Additional Information For questions or more information concerning this online CE activity,please visit the AANP Help Center to find answers to frequently asked questions and request assistance.
1.25 Contact Hour(s) of CE, 0.5 of which may be applied towards Pharmacology
Adding Registration, Please wait...
